New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Table 1

Demographic and clinical features of our cohort of 14 patients.

Demographic, laboratory, and clinical data
Age (years)
Age at scleritis onset (years)
Disease duration (years)
HLA ()	HLA-B51 (4)
	HLA-B27 (1)
	HLA-B35 (1)
Female/male ()	8/6
Eye disease	eyes
Anterior diffuse scleritis	11 (57.89%)
Anterior nodular scleritis	4 (21.05%)
Anterior necrotizing scleritis	1 (5.26%)
Posterior scleritis	3 (15.80%)
Concomitant uveitis	4 (4 AU)
Associated keratitis	3 PUK
Associated systemic disease
Rheumatoid arthritis	7
Granulomatosis with polyangiitis	2
Microscopic polyangiitis	1
Psoriatic arthritis	1
Familial Mediterranean fever	1

AU: anterior uveitis; HLA: human leukocyte antigen; PUK: peripheral ulcerative keratitis; SD: standard deviation.